JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
QUICK SEARCH:   [advanced]


     

J Am Coll Cardiol, 2006; 47:2164-2171, doi:10.1016/j.jacc.2006.01.068 (Published online 12 May 2006).
© 2006 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moses, J. W.
Right arrow Articles by Mehran, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moses, J. W.
Right arrow Articles by Mehran, R.

Drug-Eluting Stents in the Treatment of Intermediate Lesions

Pooled Analysis From Four Randomized Trials

Jeffrey W. Moses, MD, FACC*,1,*, Gregg W. Stone, MD, FACC*,2, Eugenia Nikolsky, MD, PhD, FACC*, Gary S. Mintz, MD, FACC*, George Dangas, MD, PhD, FACC*, Eberhard Grube, MD{dagger}, Stephen G. Ellis, MD, FACC{ddagger},3, Alexandra J. Lansky, MD, FACC*, Giora Weisz, MD*, Martin Fahy, MSc*, Yingbo Na, MSc*, Mary E. Russell, MD, FACC§,4, Dennis Donohoe, MD||,5, Martin B. Leon, MD, FACC*,6 and Roxana Mehran, MD, FACC*

* Columbia University Medical Center and the Cardiovascular Research Foundation, New York, New York
{dagger} Heart-Center Siegburg, Siegburg, Germany
{ddagger} Cleveland Clinic Foundation, Cleveland, Ohio
§ Boston Scientific Corp, Natick, Massachusetts
|| Cordis Corp., Warren, New Jersey


Figure 1
View larger version (13K):

[in a new window]
  		Figure 1 One-year survival free from major adverse cardiac events (MACE) of patients with intermediate lesions randomized to drug-eluting stents (DES) versus bare-metal stents (BMS). MI = myocardial infarction; TVR = target vessel revascularization.

 

Figure 2
View larger version (18K):

[in a new window]
  		Figure 2 Rates of major adverse cardiac events (MACE) in patients with intermediate lesions in studies in which intervention was deferred based on physiologic lesion assessment (fractional flow reserve ≥0.75) or intravascular ultrasound analysis (minimal cross-sectional area >4.0 mm2) (7–11) vs. the current pooled analysis of drug-eluting stent (DES)-treated patients from four randomized trials.

 




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2006 by the American College of Cardiology Foundation.